Dogwood Therapeutics Inc (DWTX)

May 05, 2025

Dogwood Therapeutics Inc expected to post a loss of $2.37 a shareEarnings Preview - TradingView

May 05, 2025

May 01, 2025

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard

May 01, 2025

May 01, 2025

Exclusive Access: Dogwood Therapeutics CEO Hosts Private Investor Meetings at Prestigious NYC Conference - Stock Titan

May 01, 2025

Apr 26, 2025

Dogwood Therapeutics (NASDAQ:DWTX) Upgraded at HC Wainwright - Defense World

Apr 26, 2025

Apr 23, 2025

HC Wainwright & Co. Upgrades Dogwood Therapeutics (DWTX) - Nasdaq

Apr 23, 2025

Apr 23, 2025

HC Wainwright Upgrades Dogwood Therapeutics to Buy From Neutral - marketscreener.com

Apr 23, 2025

Apr 23, 2025

Financial Metrics Unveiled: Dogwood Therapeutics Inc (DWTX)’s Key Ratios in the Spotlight - DWinneX

Apr 23, 2025

Apr 23, 2025

Best Biotech Stocks To Watch Today – April 21st - Defense World

Apr 23, 2025

Apr 22, 2025

Dogwood Therapeutics Inc (NASDAQ: DWTX) Has Been Trading Down. What Are The Prospects For The Future? - Stocksregister

Apr 22, 2025

Apr 22, 2025

You might want to take a look at Dogwood Therapeutics Inc (DWTX) now - Sete News

Apr 22, 2025

Apr 21, 2025

You Should Read This Analysis Before Investing in Dogwood Therapeutics Inc (NASDAQ:DWTX) - uspostnews.com

Apr 21, 2025

Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 15, 2025

Apr 15, 2025

Dogwood Therapeutics (DWTX) Begins Phase 2b Trial for Halneuron - GuruFocus

Apr 15, 2025

Apr 15, 2025

Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance - GuruFocus

Apr 15, 2025

Apr 12, 2025

Dogwood Therapeutics (DWTX) Regains Nasdaq Compliance with Equit - GuruFocus

Apr 12, 2025

Apr 11, 2025

Dogwood Therapeutics regains Nasdaq compliance By Investing.com - Investing.com South Africa

Apr 11, 2025

Apr 11, 2025

Dogwood Therapeutics regains Nasdaq compliance - Investing.com

Apr 11, 2025

Apr 11, 2025

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation Of Compliance - marketscreener.com

Apr 11, 2025

Apr 11, 2025

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance - GlobeNewswire

Apr 11, 2025

Apr 11, 2025

Nasdaq Delisting Risk Eliminated: Dogwood Therapeutics Secures Future with $17.5M War Chest - Stock Titan

Apr 11, 2025

Apr 09, 2025

Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.

Apr 09, 2025

Apr 09, 2025

Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight - GlobeNewswire

Apr 09, 2025

Apr 04, 2025

DWTX: Interim Data for Phase 2b Trial in 4Q25… - Yahoo Finance

Apr 04, 2025

Apr 04, 2025

Dogwood Therapeutics regains compliance with Nasdaq - MSN

Apr 04, 2025

Apr 03, 2025

Dogwood Therapeutics Announces Nasdaq Compliance Regained - Nasdaq

Apr 03, 2025

Apr 03, 2025

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance - GlobeNewswire

Apr 03, 2025

Apr 01, 2025

Dogwood Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks

Apr 01, 2025

Mar 31, 2025

Dogwood Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 31, 2025

Mar 31, 2025

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 31, 2025

Mar 31, 2025

Dogwood Strengthens Balance Sheet with $24M Capital Actions as Halneuron Trial Progresses - Stock Titan

Mar 31, 2025

Mar 18, 2025

Dogwood Therapeutics begins Phase 2b trial for neuropathic pain By Investing.com - Investing.com South Africa

Mar 18, 2025

Mar 18, 2025

DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet… - Zacks Small Cap Research

Mar 18, 2025

Mar 18, 2025

Dogwood Therapeutics Begins Dosing in Mid-Stage Study of Halneuron for Chemotherapy-Related Neuropathic Pain - Marketscreener.com

Mar 18, 2025

Mar 18, 2025

Dogwood Therapeutics begins Phase 2b trial for neuropathic pain - Investing.com

Mar 18, 2025

Mar 18, 2025

Dogwood Therapeutics Announces Dosing of First Patient in - GlobeNewswire

Mar 18, 2025

Mar 18, 2025

Revolutionary Non-Addictive Pain Treatment Enters Critical Phase 2b Trial for Cancer Patients - StockTitan

Mar 18, 2025

Mar 14, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

Mar 14, 2025

Mar 13, 2025

Dogwood Therapeutics announces pricing of $4.8 million offering - MSN

Mar 13, 2025

Mar 13, 2025

Dogwood Therapeutics Launches Registered Direct Offering; Shares Plunge -March 13, 2025 at 09:40 am EDT - Marketscreener.com

Mar 13, 2025

Mar 13, 2025

Dogwood Therapeutics secures $4.8 million in direct offering By Investing.com - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

Dogwood Therapeutics secures $4.8 million in direct offering - Investing.com

Mar 13, 2025

Mar 13, 2025

Dogwood Therapeutics Secures $4.8 Million in Direct Offering to Advance Halneuron® Phase 2b Trial and Fund Operations Through Q1 2026 - Nasdaq

Mar 13, 2025

Mar 13, 2025

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 - GlobeNewswire

Mar 13, 2025

Mar 13, 2025

Dogwood Secures Critical Funding for Revolutionary Pain Treatment: What's Next for Halneuron? - StockTitan

Mar 13, 2025

Mar 12, 2025

Dogwood Therapeutics clears debt with equity swa By Investing.com - Investing.com Australia

Mar 12, 2025

Mar 12, 2025

Dogwood Therapeutics converts existing debt to equity -March 12, 2025 at 10:34 am EDT - Marketscreener.com

Mar 12, 2025

Mar 12, 2025

Dogwood Therapeutics Strengthens Balance Sheet with Debt Conversion - TipRanks

Mar 12, 2025

Mar 12, 2025

Dogwood Therapeutics clears debt with equity swa - Investing.com

Mar 12, 2025

Mar 12, 2025

Dogwood Therapeutics Announces Debt-to-Equity Exchange with CK Life Sciences, Strengthening Financial Position for Clinical Trials - Nasdaq

Mar 12, 2025

Mar 12, 2025

Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward - Financial Post

Mar 12, 2025

Mar 12, 2025

Dogwood Therapeutics, Inc. Announces Conversion of Existing - GlobeNewswire

Mar 12, 2025